Catalent Inc/ US1488061029 /
6/20/2024 10:10:00 PM | Chg. -0.25 | Volume | Bid10:04:53 AM | Ask10:04:53 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
54.82USD | -0.45% | 1.47 mill. Turnover: 55.84 mill. |
55.14Bid Size: 200 | 59.99Ask Size: 100 | 9.92 bill.USD | - | - |
GlobeNewswire
5/28
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...
GlobeNewswire
5/17
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...
GlobeNewswire
5/14
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
GlobeNewswire
5/8
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cance...
GlobeNewswire
4/26
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger – CTLT, MGRC, CHRD, HRT
GlobeNewswire
4/11
Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings
GlobeNewswire
4/4
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger – NS, CTLT, SCX, EVBG
GlobeNewswire
3/7
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. -...
GlobeNewswire
3/1
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...
GlobeNewswire
3/1
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...
GlobeNewswire
2/28
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. -...